Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Tuberculosis01:23

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Growth Differentiation Factor-15 Could Predict Decreased Hemoglobin in Tuberculosis Treated With Linezolid-Containing Regimen.

The clinical respiratory journal·2026
Same author

Diagnostic Performance of New Commercial Interferon-Gamma Release Assays for Mycobacterium tuberculosis Infection: An Updated Systematic Review and Meta-analysis.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Treatment outcomes and drug-related adverse events across four short-course RR-TB regimens in South Africa: A retrospective analysis.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

Strength of ATLAS or lady luck in a sepsis management trial?

The Lancet. Infectious diseases·2026
Same author

Population Pharmacokinetic Modeling of Standard- and High-Dose Rifampicin for Tuberculosis Preventive Therapy in the 2R2 Randomized Controlled Trial.

The Journal of infectious diseases·2026
Same author

Functional Outcomes, Lung health and Livelihood Outcomes among people With Tuberculosis (FOLLOW-TB): study protocol for a multicentre, prospective cohort study in Canada.

BMJ open·2025

Related Experiment Video

Updated: Jun 28, 2026

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

Costs for tuberculosis care in Canada.

Dick Menzies1, Megan Lewis, Olivia Oxlade

  • 1Montreal Chest Institute, 3650 St-Urbain, Rm K1.24, Montreal, QC. dick.menzies@mcgill.ca

Canadian Journal of Public Health = Revue Canadienne De Sante Publique
|November 18, 2008
PubMed
Summary

Government spending on tuberculosis (TB) in Canada reached $74 million in 2004, with most funds directed towards treatment rather than prevention. Significant regional disparities in TB expenditure were observed across the country.

More Related Videos

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

Related Experiment Videos

Last Updated: Jun 28, 2026

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

Area of Science:

  • Public Health
  • Health Economics
  • Epidemiology

Background:

  • Tuberculosis (TB) remains a significant public health concern globally and in Canada.
  • Understanding the economic burden of TB is crucial for effective resource allocation and policy development.
  • Previous estimates of TB-related expenditures in Canada were limited in scope.

Purpose of the Study:

  • To estimate total tuberculosis (TB)-related expenditures by governments and third parties in Canada for the year 2004.
  • To compare TB spending across different activities, governmental jurisdictions, and geographic regions.
  • To provide a comprehensive financial overview of TB control efforts in Canada.

Main Methods:

  • Health system costs, including public health, were assessed using self-administered questionnaires sent to federal, provincial, and territorial health departments and laboratories.
  • Hospitalization data were sourced from the Canadian Institute for Health Information.
  • Costs for patient care were derived from published literature; patient and family costs were excluded.

Main Results:

  • Total TB-related expenditures in Canada in 2004 amounted to $74 million ($47,290 per active TB case).
  • Provincial/territorial governments bore the largest share (72%), with active TB treatment accounting for 59% of these costs.
  • Significant regional variations in per-case expenditure were noted, with the Northern Territories showing the highest costs and Atlantic provinces the lowest.

Conclusions:

  • Canadian government expenditures on TB in 2004 were substantial, with nearly 60% allocated to curative services and 40% to prevention and control.
  • Observed regional differences in spending likely indicate variations in healthcare accessibility and the intensity of interventions in areas with higher TB transmission.
  • The findings highlight the need for targeted resource allocation to address regional disparities and strengthen TB prevention and control strategies.